Unresectable Fibrolamellar CarcinomaPhase 1/2NCT04380545Papers
Nivolumab, Fluorouracil, and Interferon Alpha 2B
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
What the film says
Hepatocellular carcinoma is among the deadliest cancers worldwide; once it spreads, treatments add months, not years.
The idea: a marker found on nearly every liver cancer cell but not on healthy adult liver, as a target for engineered T cells.
That marker is glypican-3. At the NIH Clinical Center, a patient's T cells are collected, given a humanized receptor for glypican-3, and returned in a single infusion after three days of chemotherapy clears space. Because the protein is absent from normal liver, the hope is that the cells attack tumor and spare the organ around it.
An early safety study for adults whose tumor tests positive, including other cancers carrying the marker. Tim Greten leads it in Bethesda. Public record; not medical advice.
Sources behind this film
HCC among the most common and deadly cancers; short life expectancy when advanced; GPC3 in nearly all HCC, undetectable in normal adult liver; Novel humanized anti-GPC3 CAR; leukapheresis; Cy ×3 / Flu ×2; single infusion day 0; Adults ≥18; GPC3 ≥25% by IHC; other GPC3+ solid tumors eligible (+1 more lines)
The drug
Daily x 3 doses on Day -3, -2, -1 300 mg/m2 IV infusion (200 mg/m^2 in Dose Level -1)
Daily x 2 doses on Day -2 and -1 30 mg/m^2 IV infusion administered following cyclophosphamide
Background: * Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second leading cause of cancer-associated mortality with an average life expectancy of 6-9 months * Despite the success of several studies showing efficacy in treating HCC, most clinical trials have failed to prove a survival advantage. * Adoptive T-cell therapy exploits the natural ability of T-cells to recognize and eliminate their target. * GPC3 is a cell surface protein that is expressed in nearly all HCC yet is undetectable in normal adult hepatic tissues. * GPC3 is also expressed strongly in some non-HCC solid tumor malignancies. * We want to evaluate the role of GPC3 targeted chimeric antigen receptor (CAR)-T cells in advanced GPC3 expressing HCC as well as other advanced solid tumor malignancies with GPC3 expression.
The study
Background: A new cancer treatment takes a person s own T cells, modifies them in a laboratory so they can better fight cancer cells, and then gives them back to the person. Researchers want to see if this treatment can help people with a certain types of cancer. Objective: To see if a personalized immune treatment, anti-GPC3 CAR-T cells, is safe. Eligibility: Adults aged 18 years and older who have Glypican-3 (GPC3) positive solid tumor malignancy.
Design: Participants will be screened with the following: Blood and urine tests Medical history Physical exam Heart function tests Review of their symptoms and their ability to perform their normal activities Tumor biopsy Imaging scan of the chest, abdomen, and pelvis Participants will have leukapheresis. They may have an IV (intravenous catheter, a small tube put into an arm vein) inserted into each arm or get a central line. Blood will be removed.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.